Exposure of endothelial cells to physiological levels of myeloperoxidase-modified LDL delays pericellular fibrinolysis

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Boudjeltia, Karim Zouaoui ^a   Daher, Jalil ^a,d   van Antwerpen, Pierre ^a   Moguilevsky, Nicole ^b   Delree, Paul ^c   Ducobu, Jean ^a   Raes, Martine ^b   Badran, Bassam ^d   Vanhaeverbeek, Michel ^a   Brohee, Dany ^a   Remacle, Claude ^e   Vanhamme, Luc ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

^c Pathology and Genetic Institute   (Belgium)

^d LEBANESE UNIVERSITY   (Lebanon)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;

ARTICLE; CELL STRAIN; CELL STRAIN EA.HY926; CELL SURFACE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; EUGLOBULIN LYSIS TEST; FIBRINOLYSIS; HUMAN; HUMAN CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER;

CELL MEMBRANE; FIBRINOLYSIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, LDL; MYOCYTES, SMOOTH MUSCLE; PEROXIDASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862546901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038810     Document Type: Article

References (50)

1. Moore KJ, Tabas I, (2011) Macrophages in the pathogenesis of atherosclerosis. Cell. 145(3): 341-55.
2. Woollard KJ, Geissmann F, (2010) Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 7(2): 77-86.
3. William KJ, Tabas I, (1995) The response to retention hypothesis. Arterioscler Thromb. 15: 551-561.
4. Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, et al. (2000) Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalisation of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 67: 4495-4503.
5. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, et al. (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 286: 2136-2142.
6. Daugherty A, Dum JL, Rateri L, Heinecke JW, (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 94: 437-444.
7. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, et al. (2000) Consequence of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104: 10-15.
8. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, et al. (2003) Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 108, 1440-1445.
9. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, et al. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 349; 1595-1604.
10. Carr AC, Myzak MC, Stocker R, Me Call MR, Frei B, (2000) Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis. FEBS letters. 487: 176-180.
11. Astrup T, (1956) The biological significance of fibrinolysis. Lancet 2: 525-569.
12. Woolf N, (1978) Thrombosis and atherosclerosis. In: AB Chandler, Euremius K, Mc Milly CG, Nelson CB, Schwartz CJ, Wessler S, eds: The thrombotic Process in Atherogenesis. New York: Plenum Publishing 1978: 145-167.
13. Zouaoui Boudjeltia K, Guillaume M, Henuzet C, Delrée P, Cauchie P, et al. (2006) Fibrinolysis and cardiovascular risk factors: association with fibrinogen, lipids, and monocyte count. Eur J Intern Med. 17(2): 102-8.
14. Cesaman-Maus G, Hajjar KA, (2005) Molecular mechanisms of fibrinolysis. Br J Haematol. 129: 307-321.
15. Mazzolai L, Silacci P, Bouzourene K, Daniel F, Brunner H, et al. (2002) Tissue factor activity is upregulated in human endothelial cells exposed to oscillatory shear stress. Thromb Haemost. 87: 1062-1068.
16. Qi J, Kerutzer DL, (1995) Fibrin activation of vascular endothelial cells. J Immunol. 155: 867-876.
17. Schleef RR, Birdwell CR, (1984) Biochemical changes in endothelial cell monolayers induced by fibrin deposition in vitro. Arteriosclerosis. 3: 14-20.
18. Dang CV, Bell WR, Kaiser D, Wong A, (1985) Disorganisation of cultured vascular endothelial cell monolayers integrity of cultured vascular endothelial cells by fibrinogen fragment D. Science. pp. 1487-1490.
19. Qi J, Goralnick S, Kreutzer DL, (1997) Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood. 90: 3595-3602.
20. Moguilevsky N, Garcia-Quintana Ljacquet A, Tournay C, Fabry L, et al. (1991) Structural and biological properties of human recombinant myeloperoxidase produced by Chinese hamster ovary cell lines. Eur J Biochem. 197: 605-614.
21. Moguilevsky N, Zouaoui Boudjeltia K, Babar S, Delrée P, Legssyer I, et al. (2004) Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem Biophys Res Commun. 323: 1223-1228.
22. Hajjar KA, Reynolds CM, (1994) Alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J Clin Invest. 93(2): 703-10.
23. Hajjar KA, (1995) Cellular receptors in the regulation of plasmin generation. Thromb Haemost. 74(1): 294-301.
24. Fukao H, Ueshima S, Takaishi T, Okada K, Matsuo O, (1997) Enhancement of tissue-plasminogen activator (t-PA) activity by purified t-PA receptor expressed in human endothelial cells. Biochemica Biophysica Acta. 1536: 111-120.
25. Nagase M, Abe J, Takahashi K, Ando J, Hirose S, et al. (1198) Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene. J Biol Chem. 273(50): 33702-7.
26. Ohtani K, Suzuki Y, Eda S, Kawai T, Kase T, et al. (2001) The membrane-type collectin CL-P1 is a scavenger receptor on vascular endothelial cells. J Biol Chem. 276(47): 44222-8.
27. Zouaoui Boudjeltia K, Cauchie P, Remacle C, Guillaume M, Brohée D, et al. (2002) A new device for measurement of fibrin clot lysis: application to the euglobulin clot lysis time. BMC Biotechnol. 2: 8.
28. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, et al. (1998) Endothelial cells in physiology and in pathophysiology of vascular disorders. Blood. 91: 3527-3561.
29. Handt S, Jerome WG, Tietze L, Hantgan RR, (1996) Plasminogen Activator Inhibitor-1 secretion by endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: evidence for a key role of endothelial cells in thrombolytic resistance. Blood. 10: 4204-4213.
30. Grosjean A, Zouaoui Boudjeltia K, Piagnerelli M, Vanhaeverbeek M, (2005) Endotoxin enhances the fibrinolytic activity of monocytes incorporated in a fibrin clot. Crit Care (abstract).
31. Ellis V, Whawell SA, (1997) Vscular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells. Blood. 90,2312-2322.
32. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, et al. (2004) A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 6(2): 97-105.
33. Hoshikawa H, Sawamura T, Kakutani M, Aoyama T, Nakamura T, et al. (1998) High affinity binding of oxidized LDL to mouse lectin-like oxidized LDL receptor (LOX-1). Biochem Biophys Res Commun. 245(3): 841-6.
34. Aoyama T, Fujiwara H, Masaki T, Sawamura T, (1999) Induction of Lectin-like Oxidized LDL Receptor by Oxidized LDL and Lysophosphatidylcholine in Cultured Endothelial Cells. Journal of Molecular and Cellular Cardiology. 31(12): 2101-2114.
35. Sobel MI, Winkel CA, Macy LB, Liao P, Bjornsson TD, (1995) The regulation of plasminogen activators and plasminogen activator inhibitor type 1 in endothelial cells by sex hormones. Am J Obstet Gynecol. 173(3): 801-8.
36. Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, et al. (2006) Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl Von Rokitansky and Rudolph Virchow. Virchows arch 449: 96-103.
37. Sueishi K, Ichikawa K, Kato K, Nakagawa K, Chen YX, (1998) Atherosclerosis: coagulation and fibrinolysis. Semin Thromb Hemost. 24(3): 255-60.
38. Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB, (1999) Emerging Noninvasive Biochemical Measures to Predict Cardiovascular Risk. Arch Intern Med. 159: 237-245.
39. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, et al. (1995) Association of fibrinolytic parameters with early atherosclerosis, the ARIC study. Circulation. 91: 284-290.
40. Thompson SG, Kienast J, Pyke SD, Haverkate F, Van Loo JC, (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332: 635-641.
41. Woollard KJ, Geissmann F, (2010) Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol. 7: 77-86.
42. Emeis JJ, Edgell C-JS, (1988) Fibrinolytic properties of a human endothelial hybrid cell line. Blood. 71: 1669-1675.
43. Zhang R, Ma A, Urbanski SJ, McCafferty DM, (1990) Endothelium specific weibel-palade bodies in a continuous human cell line Ea.hy926. In Vitro Cell Dev Biol. 26: 1167-72.
44. Rieber AJ, Marr HS, Comer MB, Edgell CJ, (1193) Extent of differentiated gene expression in the human endothelium-derived EA.hy926 cell line. Thromb Haemost. 69(5): 476-80.
45. Edgell CJ, Haizlip JE, Bagnell CR, Packenham JP, Harrison P, et al. (1990) Wilbourn B, Madden VJ. Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cell Dev Biol. 26(12): 1167-72.
46. Beretz A, Freyssinet JM, Gauchy J, Schmitt DA, Klein-Soyer C, et al. (1989) Stability of the thrombin-thrombomodulin complex on the surface of endothelial cells from human saphenous vein or from the cell line EA.hy 926. Biochem J. 259(1): 35-40.
47. Bouïs D, Hospers GA, Meijer C, Molema G, Mulder NH, (2001) Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 4(2): 91-102.
48. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, et al. (1990) Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost. 19 63(1): 82-6.
49. Cesarman-Maus G, Hajjar KA, (2005) Molecular mechanisms of fibrinolysis. Br J Haematol. 129(3): 307-21.
50. Sánchez MC, Chiabrando GA, Vides MA, (2001) Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP). Arch Biochem Biophys. 389(2): 218-22.